Chronic myelogenous leukemia

Current Opinion in Hematology

Volumn 6, Issue 4, 1999, Pages 241-246

  Raymond Osarogiagbon, U ^a   McGlave, Philip B ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CARBOPLATIN; PREDNISONE; VINCRISTINE;

APOPTOSIS; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE MARKER; DRUG MECHANISM; GENE REPRESSION; GENETIC RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE TRANSFER; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; TRANSLOCATION, GENETIC;

EID: 0032797040     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199907000-00008     Document Type: Review

References (66)

1. Al-Amin A, Lennartz K, Runde V, Seeber S, Opalka B, Kloke O: Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998, 104:45-47.
2. + cells. Br J Haematol 1998, 102:759-767.
3. + cells. Blood 1998, 92:2461-2470.
4. + cells with breakpoint-specific antisense oligonucleotides increased CML progenitor cell adhesion to stroma and decreased cell proliferation.
5. Bhatia R, Verfaillie CM: The effect of interferon-α on β-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia. Leuk Lymphoma 1998, 28:241-254. This is an excellent overview of the topic.
6. Kimura A, Kawaishi K, Sasaki A, Hyodo H, Oguma N: L-selectin expression in CD34 positive cells in chronic myeloid leukemia. Leuk Lymphoma 1998, 28:389-404.
7. Amarante-Mendez GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR: Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998, 16:1383-1390. These authors present evidence showing that the BCR-ABL gene product has powerful antiapoptotic properties that are independent of the phase of the cell cycle. BCR-ABL-specific antisense oligonucleotides restore sensitivity to apoptosis.
8. Amarante-Mendez GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K: BCR-ABL gene products exert their antiapoptotic effects against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 1998, 91:1700-1705. This paper attempts to explain the mechanism of BCR-ABL-induced resistance to apoptosis. Resistance is mediated through prevention of cytosolic accumulation of cytochrome c and activation of caspase c, both of which occur upstream of the final common pathway to apoptosis.
9. Wark G, Heyworth CM, Spooncer E, Czaplewski L, Francis JM, Dexter TM, Whetton AD; Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 α. Oncogene 1998, 16:1319-1324.
10. Owen-Lynch PJ, Czaplewski LG, Hunter MG, Whetton AD: The growth inhibitory role and potential clinical value of macrophage inflammatory protein 1 alpha in myeloid leukaemias. Leuk Lymphoma 1998, 30:41-53.
11. Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, et al.: Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol 1998, 100:295-303.
12. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG: BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998, 16:335-348. This paper presents more evidence showing that BCR-ABL confers protection against apoptotic signals.
13. Verfaillie CM: Biology of chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998, 12:1-29. This is an excellent and comprehensive review of the BCR-ABL gene and the effects of its products on cell signaling.
14. Wang JC, Lapidot T, Cashman JC, Doedens M, Addy L, Sutherland DR, et al.: High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998, 91:2406-2414.
15. Dazzi F, Capelli D, Hasserjian R, Cotter F, Corbo M, Pletti A, et al.: The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 1998, 92:1390-1396. This paper details the engraftment characteristics and cell kinetics of a new murine model of CML
16. BCR-ABL.
17. Aguiar RC: Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 1998, 29:17-26.
18. Goldman JM: Chronic myeloid leukemia. Curr Opin Hematol 1997, 4:277-285.
19. Roman J, Martin C, Torres A, Garcia A, Andres P, Garcia MJ, Baiget M: Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia. Leuk Lymphoma 1998, 28:541-550.
20. Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW: A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998, 92:2315-2321. This is an examination of the utility of fluorescent in situ hybridization done using probes for BCR and ABL1 on peripheral blood samples and marrow. Residual disease in patients in complete cytogenetic remission was equally identifiable in both types of samples. It may not be necessary to collect marrow samples so often to monitor therapy.
21. Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, Duba HC: Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosom Cancer 1998, 21:90-100.
22. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P: Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998, 39:372-374.
23. Best PJ, Daoud MS, Pittelkow MR, Petitt RM: Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998, 128:29-32.
24. Russo D, Regazzi M, Sacchi S, Visani G, Lazzarino M, Avvisati G, et al.: Alltrans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. Leukemia 1998, 12:449-454.
25. Trapp OM, Beykirch MK, Petrides PE: Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 1998, 24:9-13.
26. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J, Maloisel F, et al.: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia, N Engl J Med 1997, 337:223-229.
27. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M: GM. CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 1998, 12:860-864.
28. The Benelux CML Study Group: Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α 2b for chronic myeloid leukemia. Blood 1998, 91:2713-2721.
29. Wilhelm M, Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM: Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia 1998, 12:65-70.
30. Reiffers J, Taylor K, Gluckman E, Gorin NC, Mahon FX, Miclea JM, et al.: Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant α-interferon. Br J Haematol 1998, 102:639-646.
31. Tomas JF, Lopez-Lorenzo JL, Requena MJ, Agular R, Steegmann JL, Camara R, et al.: Absence of influence of prior treatment with interferon on the outcome of allogoneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1998, 22:47-51.
32. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, et al.: Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998, 92:394-401.
33. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998, 90:850-858. This meta-analysis of 14 studies (P = 1573) is an attempt to develop a system with which to predict responses to interferon on the basis of initial clinical and with which to predict responses to interferon on the basis of initial clinical and hematologic criteria.
34. Sacchi S, Kantarjian HM, Smithe TL, O'Brien S, Pierce S, Kornblau S, et al.: Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 1998, 16:882-889. This retrospective analysis of 274 patients treated with interferon was done to identify early predictors of nonresponse. Such predictors could be used to support consideration of alternative, investigational therapy.
35. Cornelissen JJ, Ploemacher RE, Wognum BW, Borsboom A, Kluin-Nelemans HC, Hagemeijer A, Lowenberg B: An in vitro model for cytogenetic conversion in CML, Interferon-α preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. J Clin Invest 1998, 102:976-983.
36. Gordon MY, Marley SB, Lewis JL, Davidson RJ, Nguyen DX, Grand FH, et al.: Treatment with interferon-α preferentially reduces the Ä-capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 1998, 102:710-715. This is an attempt to predict responses to interferon with an in vitro sensitivity assay. The ability to amplify granulocyte-macrophage colony forming units and suppression of this ability by interferon predicted responsiveness to interferon in 86% of cases.
37. Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I, et al.: Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood 1998, 92:981-989. This paper presents more evidence of the antiapoptotic effect of BCR-ABL. One effect of interferon in CML is to increase sensitivity to Fas-triggered apoptosis.
38. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M: Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 1998, 12:455-462.
39. BCR-ABL probably explains why patients remain in clinical and cytogenetic remission despite residual disease detectable by molecular techniques.
40. Verfaillie CM, Bhatia R, Browne P, Key NS: Interferon-α restores β 1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemia. J Lab Clin Med 1998, 131:163-169.
41. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M: Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998, 16:1526-1531.
42. Brizard F, Chomel JC, Veinstein A, Rivet J, Giraud C, Kitzis A, et al.: Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon-α therapy? Leukemia 1998, 12:1076-1080.
43. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M: Clinical course and therapy of chronic myelogenous leukemia with interferon-α and chemotherapy. Hematol Oncol Clin North Am 1998, 12:31-80. This is a comprehensive review of the history and current use of interferon in CML therapy.
44. Verfaillie CM, Bhatia R, Steinbuch M, Defor T, Hirsch B, Miller JS, et al.: Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood 1998, 92:1820-1831.
45. Pratt G, Johnson RJ, Rawstron AC, Barnard DL, Morgan GJ, Smith GM: Autologous stem cell transplantation in chronic myelogenous leukemia using Philadelphia chromosome negative blood progenitors mobilized with hydroxyurea and G-CSF. Bone Marrow Transplant 1998, 21:455-460.
46. Fogli M, Amabile M, Martinelli G, Fortuna A, Rondelli D, Ratta M, et al.: Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukemia marrow. Br J Haematol 1998, 101:119-129.
47. Heinzinger M, Waller CF, Rosenstiel A, Scheid S, Burger KJ, Lange W: Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. Leukemia 1998, 12:333-339.
48. Bhatia R, Forman SJ: Autologous transplant for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998, 12:151-172. This is a good review of an increasingly important therapy.
49. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM. Heimpel H, et al.: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 1998, 91:1810-1819. This paper compares outcomes in 548 recipients of HLA-identical sibling transplants from the International Bone Marrow Transplant Registry with outcomes in 121 recipients of hydroxyurea and 75 recipients of interferon who were enrolled in a randomized trial of the German CML Study Group. It suggests that bone marrow transplantation confers a long-term survival advantage.
50. Griesshammer M, Arnold R, Banerter M, Hafner M, Heinze B, Hertenstein B, et al.: Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol 1998, 61:7-13.
51. Dini G, Lamparelli T, Rondelli R, Lanino E, Barbanti M, Costa C, et al.: Unrelated donor marrow transplantation for chronic myelogenous leukemia. Br J Haematol 1998, 102:544-552. This study identified prognostic determinants in unrelated-donor bone marrow transplantation in 379 consecutive Italian patients with Ph+ CML.
52. Helg C, Starobinski M, Jeannet M, Chapuis B: Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998, 29:301-313. This is an excellent review of the topic.
53. Fogli M, Amabile M, Martinelli G, Fortuna A, Rondelli D, Ratta M, et al.: Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukemia marrow. Br J Haematol 1998, 101:119-129.
54. Smit WM, Rijnbeek M, van Bergen CA, Willemze R, Falenburh JH: Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant 1998, 21:553-560.
55. van Rhee F, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F, et al.: Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998, 21:1055-1061.
56. Bashey A, Shepherd S, Frankel W, Wang-Rodriguez J, Cahill T, Chamberlain M, et al.: Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation. Oncol Rep 1998, 5:281-285.
57. +) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 1998, 96:10152-10157. These authors find that adoptive immunotherapy with DLI is mediated through cytotoxic T lymphocytes against CML progenitor cells.
58. Gardiner N, Lawler M, O'Riordan JM, Duggan C, De Arce M, McCann SR: Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukemia. Bone Marrow Transplant 1998, 21:711-719.
59. Cervantes F, Villamor N, Esteve J, Montoto S, Rives S, Rozman C, Montserrat E: 'Lymphoid' blast crisis of chronic myeloid leukemia is associated with distinct clinico-haematological features. Br J Haematol 1998, 100:123-128.
60. Dutcher JP, Lee S, Paietta E, Bennett JM, Stewart JA, Wiernik PH: Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998, 12:1037-1040.
61. de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, et al.: BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998, 91:3156-3162.
62. Spiller DG, Giles RV, Grzybowski J, Tidd DM, Clark RE: Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood 1998, 91:4738-4746. The permeabilization of target cell membranes is a more efficient way to deliver anti-sense oligonucleotides into cells than is lipophilic conjugation of oligonucleotides.
63. Wright LA, Milliken S, Biggs JC, Kearney P: Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line. Antisense Nucleic Acid Drug Dev 1998, 8:15-23.
64. Scheid S, Heinzinger M, Waller CF, Lange W: Bcl-2 mRNA-targeted ribozymes: effects on programmed cell death in chronic myelogenous leukemia cell lines. Ann Hematol 1998, 76:117-125.
65. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al.: Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998, 101:2290-2296.
66. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998, 91:977-983.